GE Healthcare has agreed to supply its FlexFactory manufacturing platform to China-based Xiangxue Pharmaceutical for high-affinity and high-specificity T cell receptor (TCR) cell immunotherapy drugs.
The semi-automated end-to-end platform is intended to scale up, digitise and expedite manufacturing processes for Xiangxue’s cell therapy clinical trials and future commercialisation.
Xiangxue is working towards the development of a ‘breakthrough’ cancer treatment using a new-generation of TCR T-cell therapy.
Xiangxue Pharmaceutical chairman Yonghui Wang said: “As a new breakthrough in cancer treatment, the importance of cell immunotherapy has gained consensus by the global medical industry, offering great hope for humans to combat cancer.
“As we continue development in precision medicine, we look forward to long-term collaboration with GE Healthcare and using digital and semi-automated technologies as well as comprehensive analytical methods to help us more efficiently produce treatments for patients.”
Expected to be operational in March next year, FlexFactory for cell therapy platform is designed to ensure the stable and safe yet scalable manufacturing of cell therapy products.
It enables expedited translation from scientific research to clinical trials and subsequently industrial-scale production, thereby shortening the commercialisation cycle.
GE Healthcare Life Sciences, Greater China general manager Qing Li said: “FlexFactory will help XPH establish a standardized and large-scale manufacturing process for cell immunotherapy in line with requirements for future commercialisation.
“We look forward to continuing to support the overall development and industrialisation of China’s cell and gene therapy industry.”
The company will additionally provide Xiangxue with training services, process development, digital connectivity solutions and flexible cell processing equipment.